Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.
Researchers conclude that "more prominent warnings" are warranted for the class known as dopamine receptor agonists.
The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."
Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.
Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.
Promotions and hires for agencies and manufacturers
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.
Suit alleges Purdue's OxyContin turned eastern Kentucky into "Wild West"; AbbVie-Shire $1.6B break-up fee could be tax write-off; Lilly CEO tells WSJ that 2014 has been "toughest year."
Perceptions of vaccines impact consumers' purchasing decisions
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.